N-truncated Aβ4-x peptides in Alzheimer's disease: generation, degradation, and relationship with neuropathological hallmarks
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Göttingen, Georg-August Universität, Dissertation, 2021
- Keyword
-
Maus
Alzheimerkrankheit
Peptide
Pathogenese
Nervendegeneration
Neurogenese
Tiermodell
- Event
-
Veröffentlichung
- (where)
-
Göttingen
- (who)
-
Niedersächsische Staats- und Universitätsbibliothek Göttingen
- (when)
-
2021
- Creator
- Contributor
-
Wirths, Oliver
Outeiro, Tiago Fleming
Wouters, Fred
- URN
-
urn:nbn:de:gbv:7-21.11130/00-1735-0000-0008-59CD-E-8
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:53 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zampar, Silvia
- Wirths, Oliver
- Outeiro, Tiago Fleming
- Wouters, Fred
- Niedersächsische Staats- und Universitätsbibliothek Göttingen
Time of origin
- 2021
Other Objects (12)
The role of N-truncated Aβ peptides in Alzheimer’s Disease
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
Partial dissociation of truncated peptides influences the structural dynamics of the MHCI binding groove
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease
Optimization and characterization of D-peptides for treatment of Alzheimer’s disease
Molecular characterization of neuroprotective β-amyloid interacting peptides and autoantibodies relevant to Alzheimer’s disease
The Truncated Moment Problem
Preclinical pharmacokinetics and cerebral distribution of D-enantiomeric peptides for the treatment of Alzheimer’s disease
Estimation of medical reference limits by truncated Gaussian and truncated power normal distributions
Categorification via truncated shifted Yangians
The role of N-truncated Aβ peptides in Alzheimer’s Disease
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
Partial dissociation of truncated peptides influences the structural dynamics of the MHCI binding groove
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease
Optimization and characterization of D-peptides for treatment of Alzheimer’s disease
Molecular characterization of neuroprotective β-amyloid interacting peptides and autoantibodies relevant to Alzheimer’s disease
The Truncated Moment Problem
Preclinical pharmacokinetics and cerebral distribution of D-enantiomeric peptides for the treatment of Alzheimer’s disease
Estimation of medical reference limits by truncated Gaussian and truncated power normal distributions
Categorification via truncated shifted Yangians
The role of N-truncated Aβ peptides in Alzheimer’s Disease
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides
C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
Partial dissociation of truncated peptides influences the structural dynamics of the MHCI binding groove
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease
Optimization and characterization of D-peptides for treatment of Alzheimer’s disease
Molecular characterization of neuroprotective β-amyloid interacting peptides and autoantibodies relevant to Alzheimer’s disease
The Truncated Moment Problem
Preclinical pharmacokinetics and cerebral distribution of D-enantiomeric peptides for the treatment of Alzheimer’s disease
Estimation of medical reference limits by truncated Gaussian and truncated power normal distributions